DOP2018000134A - Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer - Google Patents

Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer

Info

Publication number
DOP2018000134A
DOP2018000134A DO2018000134A DO2018000134A DOP2018000134A DO P2018000134 A DOP2018000134 A DO P2018000134A DO 2018000134 A DO2018000134 A DO 2018000134A DO 2018000134 A DO2018000134 A DO 2018000134A DO P2018000134 A DOP2018000134 A DO P2018000134A
Authority
DO
Dominican Republic
Prior art keywords
tiadiazol
compounds
cancer treatment
methylpyridazin
methoxy
Prior art date
Application number
DO2018000134A
Other languages
English (en)
Inventor
Raymond Verschoyle Finlay Maurice
David Charles Mark
Wilhelmus Johannes Nissink Maria
James Wood Matthew
Original Assignee
Astrazeneca Ab
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Cancer Research Tech Ltd filed Critical Astrazeneca Ab
Publication of DOP2018000134A publication Critical patent/DOP2018000134A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un compuesto de Fórmula (I): o una sal farmacéuticamente aceptable del mismo, en la que: Q puede ser 5-metilpiridazin-3-ilo, 5-cloropiridazin-3-ilo, 6-metilpiridazin-3-ilo, o 6-fluoropiridazin-3-ilo; R puede ser hidrógeno, flúor, o metoxi; R1 puede ser hidrógeno, metoxi, difluorometoxi, o trifluorometoxi; y R2 puede ser metilo o etilo. El compuesto de fórmula (I) puede inhibir la glutaminasa, por ejemplo, GLS1.
DO2018000134A 2015-11-30 2018-05-29 Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer DOP2018000134A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562260787P 2015-11-30 2015-11-30

Publications (1)

Publication Number Publication Date
DOP2018000134A true DOP2018000134A (es) 2018-06-30

Family

ID=57421876

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2018000134A DOP2018000134A (es) 2015-11-30 2018-05-29 Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer

Country Status (25)

Country Link
US (1) US9938265B2 (es)
EP (1) EP3383871B1 (es)
JP (1) JP6873132B2 (es)
KR (1) KR20180083412A (es)
CN (1) CN108349967B (es)
AR (1) AR106876A1 (es)
AU (1) AU2016363719B2 (es)
BR (1) BR112018010812A2 (es)
CA (1) CA3005516C (es)
CL (1) CL2018001408A1 (es)
CO (1) CO2018006929A2 (es)
DK (1) DK3383871T3 (es)
DO (1) DOP2018000134A (es)
EA (1) EA201891240A1 (es)
ES (1) ES2759940T3 (es)
IL (1) IL258644A (es)
MX (1) MX2018006528A (es)
NI (1) NI201800065A (es)
PE (1) PE20181450A1 (es)
PH (1) PH12018501132A1 (es)
SG (1) SG11201803813UA (es)
SV (1) SV2018005701A (es)
TN (1) TN2018000126A1 (es)
TW (1) TW201730188A (es)
WO (1) WO2017093300A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
US10323028B2 (en) * 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
ES2939506T3 (es) * 2018-10-16 2023-04-24 Medshine Discovery Inc Derivado de tiadiazol y usos del mismo como inhibidor de GLS1 para el tratamiento de cáncer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642237B1 (en) * 1999-11-24 2003-11-04 Merck & Co., Inc. Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides and uses thereof
US6451828B1 (en) * 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
MY142655A (en) * 2003-06-12 2010-12-15 Euro Celtique Sa Therapeutic agents useful for treating pain
US8003806B2 (en) * 2004-11-12 2011-08-23 OSI Pharmaceuticals, LLC Integrin antagonists useful as anticancer agents
SI2421826T1 (sl) * 2009-04-20 2014-02-28 F. Hoffmann-La Roche Ag Derivati prolina kot inhibitorji katepsina
EP2782570B1 (en) * 2011-11-21 2019-09-18 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
PT2920168T (pt) * 2012-11-16 2021-10-18 Calithera Biosciences Inc Inibidores heterocíclicos de glutaminase
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
EP3092236B1 (en) * 2014-01-06 2020-08-26 Rhizen Pharmaceuticals S.A. Novel glutaminase inhibitors
WO2015138902A1 (en) * 2014-03-14 2015-09-17 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
GB201409624D0 (en) 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
TW201731511A (zh) 2015-11-30 2017-09-16 阿斯特捷利康公司 １，３，４-噻二唑化合物及其在治療癌症中之用途
US10323028B2 (en) 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer

Also Published As

Publication number Publication date
TN2018000126A1 (en) 2019-10-04
IL258644A (en) 2018-06-28
JP2019501134A (ja) 2019-01-17
NI201800065A (es) 2018-10-18
AR106876A1 (es) 2018-02-28
ES2759940T3 (es) 2020-05-12
SV2018005701A (es) 2018-11-27
ES2759940T8 (es) 2020-05-20
AU2016363719A8 (en) 2018-07-12
EP3383871B1 (en) 2019-09-11
US9938265B2 (en) 2018-04-10
WO2017093300A1 (en) 2017-06-08
CA3005516C (en) 2024-04-16
EP3383871A1 (en) 2018-10-10
AU2016363719A1 (en) 2018-07-05
TW201730188A (zh) 2017-09-01
CA3005516A1 (en) 2017-06-08
CL2018001408A1 (es) 2018-10-12
PE20181450A1 (es) 2018-09-12
KR20180083412A (ko) 2018-07-20
CO2018006929A2 (es) 2018-10-10
SG11201803813UA (en) 2018-06-28
PH12018501132A1 (en) 2019-01-21
CN108349967A (zh) 2018-07-31
US20170152254A1 (en) 2017-06-01
AU2016363719B2 (en) 2019-11-14
MX2018006528A (es) 2019-05-15
EA201891240A1 (ru) 2018-11-30
BR112018010812A2 (pt) 2018-11-27
CN108349967B (zh) 2022-02-15
JP6873132B2 (ja) 2021-05-19
DK3383871T3 (da) 2019-12-16

Similar Documents

Publication Publication Date Title
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
EA201791256A1 (ru) Производные хиназолина, применяемые для лечения вич
TW201613887A (en) Antiproliferative compounds and methods of use thereof
AR103680A1 (es) Inhibidores selectivos de bace1
MX2021014531A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
NI200900184A (es) Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer.
EA201791304A1 (ru) Производные изохинолина для лечения вич
SG10201804026WA (en) Inhibitors of influenza viruses replication
SV2018005702A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
CL2017001209A1 (es) Inhibidor de cinasa aurora a
PE20170148A1 (es) Compuestos de 1,3, 4-tiadiazol y uso de los mismos para el tratamiento del cancer
CR20180328A (es) Compuestos de isoindol
MX2021003843A (es) Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer.
CL2017002960A1 (es) Compuesto para la profilaxis o el tratamiento de daño al órgano
DOP2018000134A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer
EA201691566A1 (ru) Применение производных пиридазина для предупреждения или лечения атаксического синдрома
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
AR106849A1 (es) Compuestos de bis-piridazina y su uso en el tratamiento del cáncer
MX2015012386A (es) Inhibidores de la cinasa cdk9.
PH12017500487A1 (en) Use of heterocyclic fluoroalkenyl sulfone compounds for repelling molluscs
AR115865A2 (es) Compuestos terapéuticos
AR111017A1 (es) Sal hemisulfato de un compuesto nucleotídico para el tratamiento del virus de la hepatitis c
AR113817A1 (es) Compuestos útiles para inhibir a cdk7